- Type
- not stated
- Format
- Tabular de-identified patient-level transaction records with longitudinal journey state, plus aggregated analytic marts powering dashboards with filtering, trending and drill-down, and operational alert and event feeds to region managers and manufacturer teams
- Volume
- No vendor-stated totals. Structurally implies de-identified patient-level journey transactions in the low hundreds of millions to billions cumulatively, since each specialty patient generates dozens to hundreds of events across intake, queue state, authorisation, appeals, fill, refill, adherence and service touchpoints, across a network spanning an estimated hundreds of thousands to low millions of patients. Basis is the network operating model and per-patient event density, not any published count.
- Users
- Client-side: an estimated 2,000-10,000 named commercial, access, patient-services and trade users across manufacturer and health-system accounts, inferred from a 1,300-employee firm at roughly $200M revenue. Data subjects are the asset: a network of health systems, specialty pharmacies and e-prescribing participants covering an estimated hundreds of thousands to low millions of specialty and oncology patients. The platform is described as the single source of truth for a network, implying network-scale rather than single-client coverage.
- History
- 9 years
- Update frequency
- not stated
- Growth
- Active and large-scale — currently publishing 2024-dated product materials for a named platform, reporting roughly $200M revenue against a 1,300-person workforce and $300M raised at Series C, and positioning around integrated real-world data plus artificial intelligence for therapeutic innovation. The funding stage and headcount indicate a scaled consolidator in an investment phase rather than an emerging company, and the factsheet's emphasis on data-quality operations and contract-compliance reporting indicates an actively run network rather than a static archive.
- Launched
- STAR as currently branded is documented in the company's March 2024 materials. The company record carries an identifier from roughly 2019 and a Series C funding history, and the firm's real-world-data lineage predates its current corporate form, which was created by consolidating an established oncology real-world-data asset rather than by a new start-up. Practical reading: the underlying data programme runs back to approximately 2019 or earlier, while the STAR product surface is a 2023-2024-era presentation of it.
- Delivery
- not stated
- Entity mapping
- not stated
- Sample
- not stated
- Point-in-time
- not stated
- Licence
- not stated